Kronos Bio (NASDAQ:KRON) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Kronos Bio (NASDAQ:KRON) posted its quarterly earnings data on Tuesday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. The company had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million.

Kronos Bio Stock Down 1.7 %

NASDAQ:KRON opened at $0.93 on Wednesday. The company has a market cap of $56.26 million, a P/E ratio of -0.65 and a beta of 1.79. The firm’s 50 day moving average is $0.98 and its two-hundred day moving average is $0.96. Kronos Bio has a fifty-two week low of $0.69 and a fifty-two week high of $1.60.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.